{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Vehicle+Solution", "query": { "intervention": "Matching Vehicle Solution" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T01:19:24.994Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04030962", "title": "A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dry Eye Disease", "Dry Eye Syndrome" ], "interventions": [ { "name": "AGN-242428", "type": "DRUG" }, { "name": "AGN-231868", "type": "DRUG" }, { "name": "AGN-242428 Vehicle", "type": "OTHER" }, { "name": "AGN-231868 Vehicle", "type": "OTHER" }, { "name": "Lifitegrast 5% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 292, "start_date": "2020-03-04", "completion_date": "2022-03-18", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04030962" }, { "nct_id": "NCT04511650", "title": "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19", "Acute Respiratory Distress Syndrome (ARDS)" ], "interventions": [ { "name": "Razuprotafib Subcutaneous Solution", "type": "DRUG" }, { "name": "Placebo Subcutaneous Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyePoint Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-10-21", "completion_date": "2021-02-26", "has_results": true, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 7, "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511650" }, { "nct_id": "NCT03606057", "title": "A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-64565111", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "JNJ-64565111-matching Placebo", "type": "DRUG" }, { "name": "Moxifloxacin-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 188, "start_date": "2018-07-13", "completion_date": "2019-02-28", "has_results": false, "last_update_posted_date": "2020-03-03", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606057" }, { "nct_id": "NCT02022215", "title": "Efficacy and Safety Study of ME1111 in Patients With Onychomycosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Onychomycosis" ], "interventions": [ { "name": "ME1111 Solution, Low strength", "type": "DRUG" }, { "name": "ME1111 Solution, High strength", "type": "DRUG" }, { "name": "Matching Vehicle Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Meiji Seika Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 304, "start_date": "2013-12-19", "completion_date": "2016-03-01", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Encinitas, California • San Diego, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02022215" }, { "nct_id": "NCT07776210", "title": "Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "oGVHD", "Ocular Graft Versus Host Disease" ], "interventions": [ { "name": "d-MAPPS™ Ophthalmic Solution", "type": "BIOLOGICAL" }, { "name": "Matching vehicle control", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regenerative Ocular Immunobiologics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 5, "location_summary": "Beverly Hills, California • Palm Harbor, Florida • Boston, Massachusetts", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07776210" }, { "nct_id": "NCT03131167", "title": "Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Open-angle Glaucoma (POAG)", "Ocular Hypertension" ], "interventions": [ { "name": "SHP639 (n=60)", "type": "DRUG" }, { "name": "Placebo Comparator (n=24)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 63, "start_date": "2017-05-10", "completion_date": "2018-05-30", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 1, "location_summary": "Lexington, Massachusetts", "locations": [ { "city": "Lexington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03131167" }, { "nct_id": "NCT05039359", "title": "Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Atrial Fibrillation" ], "interventions": [ { "name": "FlecIH-103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InCarda Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 54, "start_date": "2022-04-26", "completion_date": "2023-05-22", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 18, "location_summary": "Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039359" }, { "nct_id": "NCT05180500", "title": "Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19", "Pharmacokinetics", "Safety" ], "interventions": [ { "name": "Q-Griffithsin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sharon Hillier", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2022-03-15", "completion_date": "2022-12-07", "has_results": true, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180500" }, { "nct_id": "NCT04909450", "title": "Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neurotrophic Keratitis" ], "interventions": [ { "name": "CSB-001 Ophthalmic Solution 0.1%", "type": "BIOLOGICAL" }, { "name": "Vehicle Control", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Claris Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2021-08-24", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 45, "location_summary": "Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more", "locations": [ { "city": "Cave Creek", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04909450" }, { "nct_id": "NCT04284514", "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ocular Hypertension", "Primary Open Angle Glaucoma" ], "interventions": [ { "name": "AKB-9778 Ophthalmic Solution", "type": "DRUG" }, { "name": "Placebo Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerpio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 91, "start_date": "2019-05-02", "completion_date": "2019-12-15", "has_results": false, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-09-11T01:19:24.994Z", "location_count": 2, "location_summary": "Austin, Texas • Dallas, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04284514" } ] }